

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims.

**Listing of Claims:**

1-40 (Canceled)

41. (Currently amended) A method of inhibiting the activation or mobilization of eosinophils in an individual in need thereof comprising administering to said individual a therapeutically effective amount of a polypeptide consisting of ~~an amino acid sequence shown in any one of SEQ ID NOS:23-44~~ the amino acid sequence of SEQ ID NO:48.

42. (Previously presented) The method of claim 41, wherein said polypeptide is fused to polyethylene glycol.

43. (Previously presented) The method of claim 41, wherein said polypeptide is fused to a heterologous polypeptide.

44-135 (Canceled)

136. (Currently amended) A method of inhibiting the activation or mobilization of basophils in an individual in need thereof comprising administering to said individual a therapeutically effective amount of a polypeptide consisting of ~~an amino acid sequence shown in any one of SEQ ID NOS:23-44~~ the amino acid sequence of SEQ ID NO:48.

137. (Previously presented) The method of claim 136, wherein said polypeptide is fused to polyethylene glycol.

138. (Previously presented) The method of claim 136, wherein said polypeptide is fused to a heterologous polypeptide.

139-230 (Canceled)

231. (New) A method of inhibiting the activation or mobilization of eosinophils in an individual in need thereof comprising administering to said individual a therapeutically effective amount of a polypeptide consisting of an amino acid sequence shown in any one of SEQ ID NOs:50, 51, 53, 94, 96, 97, and 99.

232. (New) The method of claim 231, wherein said polypeptide is fused to polyethylene glycol.

233. (New) The method of claim 231, wherein said polypeptide is fused to a heterologous polypeptide.

234. (New) The method of claim 231, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:50.

235. (New) The method of claim 231, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO 51.

236. (New) The method of claim 231, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO.53.

237. (New) The method of claim 231, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO 94.

238. (New) The method of claim 231, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO 96.

239. (New) The method of claim 231, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:97.

240. (New) The method of claim 231, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:99.

241. (New) A method of inhibiting the activation or mobilization of basophils in an individual in need thereof comprising administering to said individual a therapeutically effective amount of a polypeptide consisting of an amino acid sequence shown in any one of SEQ ID NOS:50, 51, 53, 94, 96, 97, and 99.

242. (New) The method of claim 241, wherein said polypeptide is fused to polyethylene glycol.

243. (New) The method of claim 241, wherein said polypeptide is fused to a heterologous polypeptide.

244. (New) The method of claim 241, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:50.

245. (New) The method of claim 241, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:51.

246. (New) The method of claim 241, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:53.

247. (New) The method of claim 241, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:94.

248. (New) The method of claim 241, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:96.

249. (New) The method of claim 241, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:97.

250. (New) The method of claim 241, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:99.